XML 58 R31.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Divestitures On January 9, 2017, Valeant entered into a definitive agreement to sell all of the outstanding equity interests in Dendreon for cash consideration of approximately $820 million. The assets and liabilities of the Dendreon business have been classified as held for sale in the consolidated balance sheet at December 31, 2016. On January 10, 2017, the Company entered into a definitive agreement to sell its interests in the CeraVe®, AcneFree™ and AMBI® skincare brands for cash consideration of approximately $1,300 million. The assets and liabilities of the CeraVe®, AcneFree™ and AMBI® skincare brands business have been classified as held for sale in the consolidated balance sheet at December 31, 2016. These transactions are expected to close in the first half of 2017, and are subject to customary closing conditions, including receipt of applicable regulatory approvals. The proceeds from these transactions are to be used to permanently repay debt under the terms of the Company’s Senior Secured Credit Facilities. See Note 6 for details on these businesses. Legal Proceedings Related to Salix securities litigation, on February 8, 2017, the parties reached an agreement in principle to settle the consolidated action, pursuant to which Salix will make a payment of $210 million. See Note 20 for further details.